Molecular aspects of prostate cancer: Recent data from the literature;Aspects moléculaires des cancers de la prostate: Données récentes de la littérature

Bulletin du Cancer

Volumn 94, Issue 6 SUPPL., 2007, Pages

  Camparo, Philippe ^a   Vieillefond, Annick ^b  

^a University of Paris Descartes   (France)

^b Hôpital Cochin ^*

Author keywords

Carcinoma; Molecular biology; Prostate

Indexed keywords

GLUTATHIONE TRANSFERASE P1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UVOMORULIN;

ANDROGENESIS; APOPTOSIS; CANCER GROWTH; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUSION; GENE INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; METASTASIS; MICROENVIRONMENT; PHENOTYPE; PROSTATE CANCER; REVIEW;

ADENOCARCINOMA; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR STEM CELLS;

EID: 34547737514     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0244     Document Type: Review

References (200)

1. Montironi R, Mazzucchelli R, Scarpelli M. Molecular techniques and prostate cancer diagnostic. Eur Urol 2003 ; 44 : 390-400.
2. Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 2006 ; 16 : 123-31.
3. Liu BC, Ehrlich JR. Proteomics approaches to urologic diseases. Expert Rev Proteomics 2006 ; 3 : 283-96.
4. Lee SW, Lee KI, Kim JY. Revealing urologic diseases by proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 2005 ; 815 : 203-13.
5. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993 ; 150 : 797-802.
6. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996 ; 274 : 1371-4.
7. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001 ; 27 : 172-80.
8. Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999 ; 2 : 9-15.
9. Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, et al. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000 ; 66 : 933-44.
10. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998 ; 20 : 175-9.
11. Cancel-Tassin G, Latil A, Valeri A, Mangin P, Fournier G, Berthon P, et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001 ; 9 : 135-42.
12. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998 ; 62 : 1416-24.
13. Bott SR, Arya M, Shergill IS, Williamson M. Molecular changes in prostatic cancer. Surg Oncol 2005 ; 14 : 91-104.
14. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk : a population-based case-control study in China. Cancer Res 2000 ; 60 : 5111-6.
15. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997 ; 94 : 3320-3.
16. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000 ; 60 : 1626-30.
17. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998 ; 90 : 1225-9.
18. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999 ; 9 : 635-9.
19. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004 ; 46 : 698-708.
20. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006 ; 10 : 100-25.
21. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, et al. Pathological and molecular mechanisms of prostate carcinogenesis : implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004 ; 91 : 459-77.
22. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation : emerging insights. Carcinogenesis 2005 ; 26 : 1170-81.
23. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997 ; 43 : 69-77.
24. Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 2005 ; 65 : 1164-73.
25. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000 ; 60 : 6111-5.
26. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002 ; 99 : 2884-9.
27. Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2004 ; 101 : 17204-9.
28. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate : stem cell biology. Urology 2003 ; 62(5 Suppl 1): 11-20.
29. Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 2004 ; 7 : 188-94.
30. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006 ; 42 : 1213-8.
31. Foster CS, Dodson A, Karavana V, Smith PH, Ke Y. Prostatic stem cells. J Pathol 2002 ; 197 : 551-65.
32. Huss WJ, Gray DR, Werdin ES, Funkhouser Jr. WK, Smith GJ. Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model. Prostate 2004 ; 60 : 77-90.
33. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005 ; 108 : 1-11.
34. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006 ; 27 : 1-22.
35. Ho SM. Estrogens and anti-estrogens : key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004 ; 91 : 491-503.
36. Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, De Carli P, et al. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 2002 ; 110 : 219-27.
37. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998 ; 35 : 165-77.
38. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004 ; 431 : 707-12.
39. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, et al. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 2002 ; 21 : 4099-107.
40. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, et al. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 2005 ; 65 : 2179-85.
41. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriprome. Oncogene 2005 ; 24 : 3847-52.
42. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 ; 310 : 644-8.
43. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006 ; 66 : 10242-6.
44. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999 ; 59 : 4180-4.
45. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients : detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 2001 ; 94 : 705-10.
46. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006 ; 45 : 717-9.
47. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006 ; 66 : 8347-51.
48. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2 : ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006 ; 66 : 8337-41.
49. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2 : ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006 ; 6 : 3396-400.
50. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006 ; 8 : 826-32.
51. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007 ; 26 : 2667-73.
52. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2 : ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependant prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006 ; 66 : 10664-70.
53. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006 ; 8 : 465-9.
54. Laxman B, Tomlins SC, Mehra R, Morris DS, Wang L, Helgeson BE, et al. Noninvasive detection of TMPRSS2 : ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006 ; 8 : 885-8.
55. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003 ; 23 : 389-401.
56. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 2005 ; 102 : 1859-64.
57. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006 ; 5 : 1886-901.
58. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003 ; 425 : 962-7.
59. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002 ; 62 : 4499-506.
60. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007 ; 52 : 89-97.
61. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006 ; 66 : 2815-25.
62. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006 ; 45 : 639-45.
63. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005 ; 8 : 393-406.
64. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, et al. Human prostate cancer and benign prostatic hyperplasia : molecular dissection by gene expression profiling. Cancer Res 2001 ; 61 : 4683-8.
65. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004 ; 101 : 811-6.
66. Ashida S, Nakagawa H, Katagiri T, Furihara M, Iiizumi M, Anazawa Y, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer : genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004 ; 64 : 5963-72.
67. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002 ; 287 : 1662-70.
68. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. P504S : a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001 ; 25 : 1397-404.
69. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004 ; 90 : 449-54.
70. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001 ; 279 : 17-31.
71. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002 ; 1 : 203-9.
72. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004 ; 113 : 913-23.
73. Lexander H, Palmberg C, Hellman U, Auer G, Hellstrom M, Franzen B, et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006 ; 6 : 4370-80.
74. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002 ; 8 : 3438-44.
75. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ. Growth factors involved in prostate carcinogenesis. Front Biosci 2005 ; 10 : 1355-67.
76. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003 ; 56 : 142-9.
77. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 2004 ; 130 : 604-14.
78. Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005 ; 93 : 964-75.
79. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001 ; 21 : 4016-31.
80. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 2004 ; 101 : 12561-6.
81. Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 2006 ; 237 : 22-32.
82. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000 ; 45 : 323-34.
83. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002 ; 21 : 2679-94.
84. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma : potential pathogenetic and prognostic implications. Cancer 2004 ; 101 : 1345-56.
85. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003 ; 201 : 204-12.
86. Goberdhan DC, Wilson C. PTEN : tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 2003 ; 12(Spec 2): R239-48.
87. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995 ; 55 : 4800-3.
88. Dong JT, Li CL, Sipe TW, Frierson Jr. HF. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001 ; 7 : 304-8.
89. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998 ; 95 : 5246-50.
90. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998 ; 17 : 1979-82.
91. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999 ; 59 : 4291-6.
92. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, et al. Nkx3.1 ; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003 ; 63 : 3886-90.
93. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer : association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002 ; 8 : 3419-26.
94. Lu L, Schulz H, Wolf DA. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 2002 ; 3 : 22.
95. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998 ; 90 : 916-20.
96. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27 (Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997 ; 3 : 2269-74.
97. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998 ; 159 : 941-5.
98. Moro L, Arbini AA, Marra E, Greco M. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006 ; 281 : 22100-7.
99. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004 ; 18 : 1926-45.
100. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006 ; 66 : 1203-12.
101. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006 ; 66 : 10040-7.
102. Katagiri Y, Hozumi Y, Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 2006 ; 42 : 215-24.
103. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997 ; 19 : 90-6.
104. Claudio PP, Zamparelli A, Garcia FU, Claudio L, Ammirati G, Farina A, et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27 (kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002 ; 8 : 1808-15.
105. Amirghofran Z, Monabati A, Gholijani N. Apoptosis in prostate cancer : bax correlation with stage. Int J Urol 2005 ; 12 : 340-5.
106. Iacopino F, Angelucci C, Lama G, Zelano G, La Torre G, D'Addessi A, et al. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. Anticancer Res 2006 ; 26 : 1849-54.
107. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006 ; 6 : 73.
108. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003 ; 9 : 4914-25.
109. Nomura T, Yamasaki M, Nomura Y, Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005 ; 14 : 993-7.
110. Serlur SR, Rubin MA. Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv Anat Pathol 2005 ; 12 : 265-70.
111. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001 ; 61 : 5038-44.
112. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004 ; 25 : 276-308.
113. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006 ; 66 : 5012-20.
114. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002 ; 99 : 11890-5.
115. Ford 3rd OH, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003 ; 170 : 1817-21.
116. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001 ; 61 : 3550-5.
117. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, et al. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995 ; 147 : 1608-14.
118. Koivisto P. Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostatic Dis 1997 ; 1 : 21-5.
119. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate : cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004 ; 28 : 928-34.
120. Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 1999 ; 189 : 219-23.
121. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, et al. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005 ; 65 : 287-98.
122. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily : functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000 ; 351 : 67-77.
123. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004 ; 23 : 527-33.
124. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor : a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003 ; 63 : 149-53.
125. Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 2002 ; 100 : 309-17.
126. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, et al. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006 ; 25 : 3905-13.
127. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994 ; 54 : 2861-4.
128. Wang C, Young WJ, Chang C. Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide. Endocrine 2000 ; 12 : 69-76.
129. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004 ; 10 : 33-9.
130. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006 ; 33 : 201-10.
131. Thompson J, Hyytinen ER, Haapala K, Rantala I, Helin HJ, Janne OA, et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 2003 ; 83 : 1709-13.
132. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004 ; 279 : 7119-30.
133. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999 ; 5 : 280-5.
134. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006 ; 66 : 5723-8.
135. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies : comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006 ; 37 : 1137-44.
136. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators : a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999 ; 96 : 5458-63.
137. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998 ; 58 : 4640-5.
138. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 2006 ; 103 : 7789-94.
139. nYang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002 ; 277 : 11336-44.
140. Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, et al. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 2004 ; 18 : 2388-401.
141. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007 : 719-33.
142. Culig Z, Bartsch G. Androgen axis in prostate cancer. J Cell Biochem 2006 ; 99 : 373-81.
143. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001 ; 1 : 34-45.
144. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells : regulation by methylation and involvement in growth regulation. Cancer Res 2000 ; 60 : 3175-82.
145. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004 ; 89 : 2434-41.
146. Cheung CP, Yu S, Wong KB, Chan LW, Lai FM, Wang X, et al. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 2005 ; 90 : 1830-44.
147. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, et al. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004 ; 32 : 777-91.
148. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer progression. Cancer Surv 1995 ; 23 : 19-32.
149. Knudsen BS, Miranti CK. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 2006 ; 99 : 345-61.
150. Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai FJ, et al. E-cadherin gene 3′-UTR C/T polymorphism is associated with prostate cancer. Urol Int 2005 ; 75 : 350-3.
151. Bonilla C, Mason T, Long L, Ahaghotu C, Chen W, Zhao A, et al. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 2006 ; 66 : 546-56.
152. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992 ; 52 : 5104-9.
153. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer : correlation with patient survival. Cancer Res 1997 ; 57 : 3189-93.
154. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996 ; 148 : 1375-80.
155. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer : a broad survey using high-density tissue microarray technology. Hum Pathol 2001 ; 32 : 690-7.
156. Bryden AA, Freemont AJ, Clarke NW, George NJ. Paradoxical expression of E-cadherin in prostatic bone metastases. BJU Int 1999 ; 84 : 1032-4.
157. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999 ; 53 : 707-13.
158. Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, et al. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res 2005 ; 65 : 483-92.
159. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006 ; 25 : 2367-78.
160. Noordzij MA, van Steenbrugge GJ, Schroder FH, Van der Kwast TH. Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999 ; 84 : 478-83.
161. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002 ; 108 : 171-82.
162. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2 : a review of the literature. J Clin Oncol 2004 ; 22 : 735-42.
163. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002 ; 191 : 208-16.
164. Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 2002 ; 50 : 38-45.
165. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 2001 ; 93 : 507-15.
166. Primakoff P, Myles DG. The ADAM gene family : surface proteins with adhesion and protease activity. Trends Genet 2000 ; 16 : 83-7.
167. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004 ; 279 : 51323-30.
168. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006 ; 8 : 319-29.
169. McCulloch DR, Akl P, Samaratunga H, Herington AC, Odorico DM. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res 2004 ; 10 : 314-23.
170. McCulloch DR, Harvey M, Herington AC. The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 2000 ; 167 : 11-21.
171. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001 ; 155 : 661-73.
172. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998 ; 51 : 161-7.
173. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 ; 362 : 841-4.
174. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000 ; 45 : 216-24.
175. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000 ; 6 : 1882-90.
176. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001 ; 7 : 1932-6.
177. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy : a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004 ; 22 : 499-506.
178. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004 ; 22 : 1655-63.
179. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, et al. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004 ; 63 : 327-32.
180. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology 2003 ; 61 : 765-9.
181. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005 ; 11 : 584-93.
182. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004 ; 58 : 193-9.
183. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005 ; 65 : 110-6.
184. Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004 ; 10 : 5137-44.
185. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999 ; 39 : 246-61.
186. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003 ; 56 : 13-22.
187. De Pinieux G, Flam T, Zerbib M, Taupin P, Bellahcene A, Waltregny D, et al. Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome : a clinicopathological and immunohistochemical study of 43 cases. J Urol 2001 ; 166 : 1924-30.
188. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001 ; 107 : 1235-44.
189. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001 ; 57 : 611-6.
190. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002 ; 62 : 917-23.
191. Koutsilieris M, Rabbani SA, Bennett HP, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987 ; 80 : 941-6.
192. Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, et al. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts : a new biological and clinical parameter for prostatic carcinoma. Oncol Res 1997 ; 9 : 419-31.
193. Bobinac D, Maric I, Zoricic S, Spanjol J, Dordevic G, Mustac E, et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 2005 ; 46 : 389-96.
194. Van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005 ; 48 : 1031-41.
195. Petricoin 3rd EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002 ; 94 : 1576-8.
196. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003 ; 62(Suppl 1): 19-35.
197. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004 ; 13 : 1303-13.
198. Taylor BS, Varambally S, Chinnaiyan AM. Differential proteomic alterations between localised and metastatic prostate cancer. Br J Cancer 2006 ; 95 : 425-30.
199. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006 ; 8 : 59-68.
200. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001 ; 61 : 5974-8.